Lilly, swinging at the king, shows Dupixent rival works in phase 3, but wait for key figures goes on

Eli Lilly is gunning for Regeneron and Sanofi’s blockbuster Dupixent. Having paid $1.1 billion to enter the IL-13 space last year, Lilly has now revealed the success of its challenger in two pivotal trials—but it's yet to share the numbers that will show whether lebrikizumab is a true contender for the throne.